Valuation: ThermoGenesis Corp

Market Cap 11.09K 9.69K 8.9K 8.3K 15.74K 1.06M 16K 107K 41.53K 518K 41.65K 40.75K 1.78M P/E 2022
-0.16x
P/E 2023 -0.08x
Enterprise Value 9.29M 8.12M 7.46M 6.95M 13.18M 885M 13.41M 89.78M 34.79M 434M 34.89M 34.14M 1.5B EV / Sales 2022
0.97x
EV / Sales 2023 1.18x
Free-Float
100%
Yield 2022 *
-
Yield 2023 -
Manager TitleAgeSince
Chief Executive Officer 55 2016-11-02
Investor Relations Contact - -
Director TitleAgeSince
Chairman 55 2016-11-02
Director/Board Member - 2023-07-13
Change 5-day change 1-year change 3-year change Capi.($)
+0.62%+5.23%+8.52%-0.24% 26.44B
+0.02%+2.17%+17.83%-8.21% 7.43B
-8.80%+5.12%+121.73%+218.24% 4.73B
-5.08%-5.64%+208.43%+163.21% 2.61B
+2.68%+8.68%+9.94%-47.47% 2.82B
-0.37%+1.61%+67.59%+43.78% 2.27B
-4.16%+1.54%+56.64%+66.86% 2.18B
-0.75%+11.09%-9.23%+41.30% 1.2B
-3.04%-3.73%+98.97%+58.48% 954M
Average -1.67%+3.32%+64.49%+59.55% 5.62B
Weighted average by Cap. -0.80%+5.82%+36.84%+31.74%

Financials

2022 2023
Net sales 10.48M 9.16M 8.41M 7.84M 14.87M 998M 15.12M 101M 39.25M 490M 39.36M 38.51M 1.69B 9.44M 8.25M 7.58M 7.07M 13.4M 899M 13.62M 91.25M 35.36M 441M 35.46M 34.69M 1.52B
Net income -11.27M -9.85M -9.04M -8.43M -15.99M -1.07B -16.26M -109M -42.2M -526M -42.32M -41.4M -1.81B -17.98M -15.71M -14.42M -13.45M -25.5M -1.71B -25.93M -174M -67.3M -839M -67.49M -66.03M -2.89B
Net Debt 6.89M 6.02M 5.53M 5.15M 9.77M 656M 9.94M 66.55M 25.79M 322M 25.86M 25.3M 1.11B 9.28M 8.11M 7.45M 6.95M 13.17M 884M 13.39M 89.67M 34.75M 433M 34.85M 34.09M 1.49B
Logo ThermoGenesis Corp
ThermoGenesis Holdings, Inc. develops and commercializes a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics. The Company provides the AutoXpress and BioArchive platforms for automated clinical bio-banking, the PXP platform for point-of-care cell-based therapies and X-Series products for cell processing services. Its product lines include Clinical Bio-Banking Applications, Point-of-Care Applications and Cell Processing. Its Clinical Bio-Banking Applications include AXP II Automated Cell Separation System and BioArchive Automated Cryopreservation System. Its Point-of-Care Applications include PXP Point-of-Care System, and PXP-1000 System. Its Cell Processing includes X-Series Products for general laboratory use: X-Lab for cell isolation, X-Wash System for cell washing and reformulation, and X-Mini for high efficiency small scale cell purification. The Company markets and sells its medical device products through independent distributors.
Employees
-